Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes - PACE-CME

Large risk reductions with SGLT inhibitor in HFrEF with or without diabetes

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Smartphone-based AF screening in the general population
Smartphone-based AF screening in the general population
ESC 2019
Smartphone-based AF screening in the general population
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
ESC 2019
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
- Prof. François Mach, MD
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
ESC 2019
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
- Prof. Freek Verheugt
Sex-related differences in ACS patients
Sex-related differences in ACS patients
ESC 2019
Sex-related differences in ACS patients
- Sanne Peters, PhD